CTOs on the Move

PreferredOne

www.preferredone.com

 
At PreferredOne, our name says it all. You, our valued members, are our preferred ones. Everything we do is for one purpose - to make your experience the best it can be.   We offer individual health insurance, family medical plans and group health insurance to fit your needs and budget, plus wellness programs to help you stay healthy. We are known for outstanding customer service and for paying claims promptly, and our representatives are available to answer any questions you have about health care coverage.   PreferredOne has served our Minnesota and upper Midwest members for almost 30 years.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

LifeScript

LifeScript is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Superior Prescriptions Pads

Superior Prescriptions Pads is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

J Sterling Industries

J Sterling Industries is a Woodbridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayside Manor

Bayside Manor is a Keansburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.